The Inferential Binding Sites of GCGR for Small Molecules Using Protein Dynamic Conformations and Crystal Structures

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2024 Aug 10

PMID 39125959

Authors

Mengru Wang

Xulei Fu

Limin Du

Fan Shi

Zichong Huang

Linlin Yang

Affiliations

Soon will be listed here.

Abstract

Glucagon receptor (GCGR) is a class B1 G-protein-coupled receptor that plays a crucial role in maintaining human blood glucose homeostasis and is a significant target for the treatment of type 2 diabetes mellitus (T2DM). Currently, six small molecules (Bay 27-9955, MK-0893, MK-3577, LY2409021, PF-06291874, and LGD-6972) have been tested or are undergoing clinical trials, but only the binding site of MK-0893 has been resolved. To predict binding sites for other small molecules, we utilized both the crystal structure of the GCGR and MK-0893 complex and dynamic conformations. We docked five small molecules and selected the best conformation based on binding mode, docking score, and binding free energy. We performed MD simulations to verify the binding mode of the selected small molecules. Moreover, when selecting conformations, results of competitive binding were referred to. MD simulation indicated that Bay 27-9955 exhibits moderate binding stability in Pocket 3. MK-3577, LY2409021, and PF-06291874 exhibited highly stable binding to Pocket 2, consistent with experimental results. However, LY2409021 may also bind to Pocket 5. Additionally, LGD-6972 exhibited relatively stable binding in Pocket 5. We also conducted structural modifications of LGD-6972 based on the results of MD simulations and predicted its analogues' bioavailability, providing a reference for the study of GCGR small molecules.

References

Sali A, Blundell T . Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol. 1993; 234(3):779-815. DOI: 10.1006/jmbi.1993.1626. View

Daina A, Michielin O, Zoete V . SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017; 7:42717. PMC: 5335600. DOI: 10.1038/srep42717. View

Sonmez A, Sabbour H, Echtay A, Rahmah A, Alhozali A, Al Sabaan F . Current gaps in management and timely referral of cardiorenal complications among people with type 2 diabetes mellitus in the Middle East and African countries: Expert recommendations. J Diabetes. 2022; 14(5):315-333. PMC: 9366572. DOI: 10.1111/1753-0407.13266. View

Zhang H, Qiao A, Yang L, Van Eps N, Frederiksen K, Yang D . Structure of the glucagon receptor in complex with a glucagon analogue. Nature. 2018; 553(7686):106-110. DOI: 10.1038/nature25153. View

Guzman C, Zhang X, Liu R, Regev A, Shankar S, Garhyan P . Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes. Diabetes Obes Metab. 2017; 19(11):1521-1528. DOI: 10.1111/dom.12958. View

Gumbiner B, Esteves B, Dell V, Joh T, Garzone P, Forgie A . Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial. Endocrine. 2018; 62(2):371-380. DOI: 10.1007/s12020-018-1597-1. View

Harmar A . Family-B G-protein-coupled receptors. Genome Biol. 2002; 2(12):REVIEWS3013. PMC: 138994. DOI: 10.1186/gb-2001-2-12-reviews3013. View

Dror R, Green H, Valant C, Borhani D, Valcourt J, Pan A . Structural basis for modulation of a G-protein-coupled receptor by allosteric drugs. Nature. 2013; 503(7475):295-9. DOI: 10.1038/nature12595. View

Pettus J, DAlessio D, Frias J, Vajda E, Pipkin J, Rosenstock J . Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study. Diabetes Care. 2019; 43(1):161-168. DOI: 10.2337/dc19-1328. View

10.

Muller W, Faloona G, Unger R . The effect of experimental insulin deficiency on glucagon secretion. J Clin Invest. 1971; 50(9):1992-9. PMC: 292125. DOI: 10.1172/JCI106691. View

11.

Huypens P, Ling Z, Pipeleers D, Schuit F . Glucagon receptors on human islet cells contribute to glucose competence of insulin release. Diabetologia. 2000; 43(8):1012-9. DOI: 10.1007/s001250051484. View

12.

Valdes-Tresanco M, Valdes-Tresanco M, Valiente P, Moreno E . gmx_MMPBSA: A New Tool to Perform End-State Free Energy Calculations with GROMACS. J Chem Theory Comput. 2021; 17(10):6281-6291. DOI: 10.1021/acs.jctc.1c00645. View

13.

Okamoto H, Kim J, Aglione J, Lee J, Cavino K, Na E . Glucagon Receptor Blockade With a Human Antibody Normalizes Blood Glucose in Diabetic Mice and Monkeys. Endocrinology. 2015; 156(8):2781-94. DOI: 10.1210/en.2015-1011. View

14.

Cheng C, Jabri S, Taoka B, Sinz C . Small molecule glucagon receptor antagonists: an updated patent review (2015-2019). Expert Opin Ther Pat. 2020; 30(7):509-526. DOI: 10.1080/13543776.2020.1769600. View

15.

Zhang H, Qiao A, Yang D, Yang L, Dai A, de Graaf C . Structure of the full-length glucagon class B G-protein-coupled receptor. Nature. 2017; 546(7657):259-264. PMC: 5492955. DOI: 10.1038/nature22363. View

16.

Peng J, Denney W, Musser B, Liu R, Tsai K, Fang L . A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design. AAPS J. 2014; 16(6):1259-70. PMC: 4389739. DOI: 10.1208/s12248-014-9648-x. View

17.

Morris G, Huey R, Lindstrom W, Sanner M, Belew R, Goodsell D . AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem. 2009; 30(16):2785-91. PMC: 2760638. DOI: 10.1002/jcc.21256. View

18.

Tillner J, Posch M, Wagner F, Teichert L, Hijazi Y, Einig C . A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials. Diabetes Obes Metab. 2018; 21(1):120-128. DOI: 10.1111/dom.13494. View

19.

Wang M, Yan H, Shi Z, Evans M, Yu X, Lee Y . Glucagon receptor antibody completely suppresses type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc Natl Acad Sci U S A. 2015; 112(8):2503-8. PMC: 4345619. DOI: 10.1073/pnas.1424934112. View

20.

Xiong Y, Guo J, Candelore M, Liang R, Miller C, Dallas-Yang Q . Discovery of a novel glucagon receptor antagonist N-[(4-{(1S)-1-[3-(3, 5-dichlorophenyl)-5-(6-methoxynaphthalen-2-yl)-1H-pyrazol-1-yl]ethyl}phenyl)carbonyl]-β-alanine (MK-0893) for the treatment of type II diabetes. J Med Chem. 2012; 55(13):6137-48. DOI: 10.1021/jm300579z. View